SYNAIRGEN PLC Logo

SYNAIRGEN PLC

Developing inhaled interferon beta treatments for severe viral lung infections in hospitalized patients.

SNG | IL

Overview

Corporate Details

ISIN(s):
GB00B0381Z20
LEI:
213800IMMTOPPDF8HD24
Country:
United Kingdom
Address:
MAILPOINT 810 LEVEL F, SO16 6YD SOUTHAMPTON
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Synairgen PLC is a specialist respiratory biotechnology company focused on developing treatments for severe viral lung infections. Founded in 2003 as a spin-off from the University of Southampton, the company's primary focus is its investigative drug candidate, SNG001. This product is an inhaled formulation of interferon beta (IFN-β), a broad-spectrum antiviral protein, designed for direct delivery to the lungs. Synairgen aims to address the significant unmet medical need for effective treatments for hospitalized patients suffering from severe respiratory illnesses caused by viruses like influenza, RSV, and SARS-CoV-2, with a particular focus on patients requiring mechanical ventilation.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-04 18:00
Business and Financial Review
Business Update
English 26.1 KB
2025-05-16 08:00
Board/Management Information
Board and Executive Leadership Changes
English 9.8 KB
2025-03-28 15:21
Post-Annual General Meeting Information
Result of General Meeting
English 18.6 KB
2025-03-11 08:00
Pre-Annual General Meeting Information
Proposed cancellation of trading on AIM
English 76.3 KB
2025-01-17 13:55
Major Shareholding Notification
Holding(s) in Company
English 51.8 KB
2025-01-16 16:42
Board/Management Information
Martin Murphy appointed as Non-Executive Director
English 17.9 KB
2025-01-16 16:42
Post-Annual General Meeting Information
Result of General Meeting and Total Voting Rights
English 13.5 KB
2025-01-15 18:37
Share Issue/Capital Change
£18m raised to fund Phase 2 INVENT clinical trial
English 14.8 KB
2024-12-20 08:00
Share Issue/Capital Change
Proposed Fundraising
English 398.7 KB
2024-10-30 19:09
Share Issue/Capital Change
Exercise of Share Options and Total Voting Rights
English 10.5 KB
2024-10-10 18:05
Post-Annual General Meeting Information
Results of AGM and Appointment of New Chairman
English 10.8 KB
2024-09-26 08:00
Interim Report
Interim Results
English 143.5 KB
2024-09-18 08:00
Board/Management Information
Appointment of New Chairman and Notice of AGM
English 17.7 KB
2024-09-05 08:00
Board/Management Information
Board Change
English 11.1 KB
2024-06-27 08:00
Earnings Release
2023 Full Year Results
English 129.1 KB

Automate Your Workflow. Get a real-time feed of all SYNAIRGEN PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for SYNAIRGEN PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
A tech group providing R&D, services, training, and investment for life sciences industries.
Spain IKM
AI-powered genome sequencing and reanalysis to diagnose rare diseases globally.
South Korea 394800
Develops antibody therapeutics and CAR-T for oncology and provides CRO services.
South Korea 174900
Clinical-stage biopharma developing therapeutics for oncology & viral infectious diseases.
South Korea 203400
ABL Bio Inc. Logo
Develops bispecific antibody therapies for oncology and neurodegenerative diseases.
South Korea 298380
Acticor Biotech Logo
Clinical-stage biopharma developing a first-in-class drug for thrombotic diseases like stroke.
France ALACT
Adecco Group AG Logo
Global talent solutions firm offering staffing, placement, career transition, and tech consulting.
Switzerland ADI1
ADforus Co., Ltd. Logo
Ad-tech firm with AI platforms for mobile marketing and publisher monetization solutions.
South Korea 397810
Adocia Logo
Biotech improving protein drug formulations for diabetes & obesity and developing cell therapies.
France ADOC
ad pepper media International N.V. Logo
Global performance marketing & audience targeting solutions for advertisers and agencies worldwide.
Germany APM

Talk to a Data Expert

Have a question? We'll get back to you promptly.